BRAF and ovarian cancer: Using a panel of human, immunocompetent genetically engineered mouse, and patient-derived tumor models, dab-SiR penetration was assessed across BRAF-mutant tumors of melanoma, anaplastic thyroid cancer, ovarian cancer, and mCRC.